China-based gene therapy Contract Research Organization (CRO) OBiO Technology (Shanghai) Co., Ltd (SHA: 688238) has announced a partnership with compatriot firm Hanxin Biotechnology (Suzhou) Co., Ltd. The collaboration is focused on the lipid nanoparticle (LNP) delivery system field, aiming to enhance the clinical application of mRNA and other nucleic acid products in areas such as vaccines and cancer treatment. Financial details of the agreement have not been disclosed.
Focus on Lipid Nanoparticle Delivery System
The partnership between OBiO Technology and Hanxin Biotechnology is designed to leverage their respective expertise in the field of lipid nanoparticle (LNP) delivery systems. LNPs are a critical component in the delivery of mRNA and other nucleic acid products, which are increasingly being used in innovative therapies for diseases such as cancer and in the development of vaccines.
Boosting mRNA Clinical Applications
The collaboration will focus on improving the efficiency and effectiveness of mRNA delivery, which is vital for the development of new treatments and vaccines. By optimizing the LNP delivery system, the partnership aims to accelerate the clinical application of these advanced therapies, potentially revolutionizing the way we approach cancer treatment and vaccine development.-Fineline Info & Tech
